Proactive Investors - Run By Investors For Investors

GW Pharma soars on news of positive trial for cannabis-based epilepsy drug

A second Phase 3 trial of the London-based company’s Epidiolex treatment for a severe form of childhood epilepsy produced positive results
stethoscope and marijuana leaf
The company focuses on developing novel therapeutics from its proprietary cannabinoid product platform

GW Pharmaceuticals PLC (NASDAQ:GWPH; ) shares climbed in premarket trade Monday, after the company said a second Phase 3 trial of its cannabis-based Epidiolex treatment for a severe form of childhood epilepsy produced positive results.

London-based GW Pharma’s lead product Epidolex, a cannabidiol oral medication for the treatment of seizures, takes aim at two types of childhood epilepsy, Dravet syndrome and Lennox-Gastaut syndrome.

GW Pharma said the trial met its primary endpoint of reducing convulsive seizures in patients suffering from Dravet syndrome. The endpoint was achieved at two dose levels, 10 mg a day and 20 mg a day, the company said in a statement.

READ: Leerink Partners starts coverage of GW Pharmaceuticals with Outperform rating and $185 price target

"The positive results from this latest Epidiolex clinical trial are very encouraging for those living with intractable seizures caused by LGS and Dravet syndrome, two extremely difficult treatment-resistant forms of epilepsy," said Philip M. Gattone, president and CEO of the Epilepsy Foundation.

The data represents the fourth positive Phase 3 pivotal trial for Epidiolex in treating Dravet syndrome and Lennox-Gastaut syndrome.

Epidiolex recently launched in the US and is now available by prescription. Leerink analyst Marc Goodman thinks Epidolex should be a blockbuster drug with sales of about $1.8 billion in 2026.

GW Pharma shares jumped 4.2% to $129.26 before the opening bell.

 

Contact Uttara Choudhury at [email protected]

Follow her on Twitter@UttaraProactive 

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full GWP profile View Profile

GW Pharmaceuticals Timeline

Related Articles

1542134062_Harvesting-hemp.jpg
November 13 2018
Ascent, viaThirty Eight Hemp Corp, will exploit the hemp market via its strategic relationship with AgTech Scientific
medical cannabis
September 30 2018
The companies will collaborate on activities to develop cannabinoid medicines as a medical option in Chile.
High Hampton Holdings set to add near term revenue to bottom line with Mojave Jane acquisition
November 12 2018
Mojave Jane is a California-licensed manufacturer of premium cannabis extracts and concentrates for buyers in the US state
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use